(Q46874592)

English

Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus

scientific article published in November 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

type 2 diabetes

0 references

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

author name string

Aaron S Kelly

1

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

Andrea M Thelen

2

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

Daniel R Kaiser

3

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

J Michael Gonzalez-Campoy

4

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

Alan J Bank

5

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

publication date

1 November 2007

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

Vascular Medicine

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

12

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

4

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

311-318

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Relationship of plasma extracellular-superoxide dismutase level with insulin resistance in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Effects of weight loss on insulin sensitivity and arterial stiffness in overweight adults

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Comparison of B-mode and echo tracking methods of assessing flow-mediated dilation.

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Endogenous Dimethylarginine as an Inhibitor of Nitric Oxide Synthesis

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome

1 reference

https://api.crossref.org/works/10.1177%2F1358863X07084200

21 January 2018

Identifiers

10.1177/1358863X07084200

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18048467

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46874592&oldid=2135536670"